Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin
A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus
1 other identifier
interventional
500
9 countries
74
Brief Summary
To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 diabetes-mellitus
Started Apr 2008
Typical duration for phase_3 diabetes-mellitus
74 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2008
CompletedFirst Submitted
Initial submission to the registry
April 24, 2008
CompletedFirst Posted
Study publicly available on registry
April 29, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2011
CompletedJune 8, 2011
June 1, 2011
3.3 years
April 24, 2008
June 6, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy
change in HbA1c from the Day 0 (V3) to Day 180 (V9) of Treatment Phase.
Secondary Outcomes (1)
To evaluate the safety, tolerability, and satisfaction with Generex Oral-lyn™ therapy when administered by the RapidMist™ Diabetes Management System
26 week
Study Arms (2)
1
EXPERIMENTALGenerex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
2
ACTIVE COMPARATORRegular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
Interventions
Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
Eligibility Criteria
You may qualify if:
- Be male or female between the ages 18 to 75 years
- Type 1 diabetes mellitus patients (according to ADA and/or WHO classification) who have \>1 year history of type 1 DM and are currently managed with daily insulin injections totalling 0.3 to 0.8 IU/kg of body weight;
- Current physical examination, vital signs and ECG at screening that reveals no clinically significant abnormalities;
- Have a body mass index (BMI) \<27;
- % (inclusively)\<Have a glycosylated haemoglobulin HbA1c
- Willing and able to follow the American Diabetes Association diet guidelines for type 1 diabetes; be able to commit to perform home blood glucose monitoring and record values as well as hypoglycemic events
- Willing to give written informed consent prior to admission into the study.
You may not qualify if:
- Have a significant active asthma or suspected abnormalities of buccal mucosa; cardiovascular, cerebrovascular, hepatic, renal, gastrointestinal, hematological, or auto-immune disease (other than auto-immune thyroid disease); history of athopy or drugs allergy
- Have evidence of unstable retinopathy (defined as pre-proliferative or proliferative retinopathy currently requiring photocoagulation therapy), nephropathy or neuropathy (gastroparesis or orthostatic hypotension);
- Have hypoglycemia unawareness;
- Have had more than one episode of severe hypoglycemia with seizure or coma or ketoacidosis within the past 12 months;
- Have a blood pressure in excess of 160/100 mmHg at the Screening visit;
- Have had any acute illness within the 2 weeks prior to screening;
- Have a history of drug or alcohol abuse that in the opinion of the Investigator would interfere with participation in the protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Generex Biotechnology Corp.lead
- OSMOS Clinical Research, Inccollaborator
- PSI Pharma Support Intlcollaborator
- Nextrials, Inc.collaborator
- eResearch Technology, Inc.collaborator
- Hoffmann-La Rochecollaborator
- ACM Pivotal Global Central Laboratorycollaborator
Study Sites (74)
Coastal Biomedical Research Inc. at Santa Monica
2001 Santa Monica Blvd Suite 390W, California, 90404, United States
The Center for Diabetes & Endocrine Care at Hollywood
1150 N. 35th Ave Suite 590, Florida, 33021, United States
Physicians Research Group at Indianapolis
7400 North Shadeland Ave, Indiana, United States
MODEL Clinical Research at Baltimore
6535 North Charles Street Suite 400N, Maryland, 21204, United States
Grunberger Diabetes Institute at Bloomfield Hills
43494 Woodward Ave Suite 208, Michigan, 48302, United States
Beth Israel Medical Center, Geral J. Friedman Diabetes Institute at New York
317 East 17th Street Room 7F05 8th Floor, New York, 10003, United States
Multiple Health Research, LLC. at Arlington
501 Rita Lane Suite 113, Texas, 76014, United States
University of Texas Southwestern Medical Center at Dallas
5323 Harry Hines Blvd, Texas, 75390-8858, United States
University Multiprofile Hospital for Active Treatment "Aleksandrovska"
1 Saint Georgi Sofiysky Saint, Sofia, 1431, Bulgaria
University Multiprofile Hospital for Active Treatment at Varna
1 Hristo Smirnensky Saint, 9010, Bulgaria
Multiprofile Hospital for Active Treatment at Stara Zagora
11 Armeyska Saint, 6003, Bulgaria
University Multiprofile Hospital for Active Treatment at Plovdiv
15A Vassil Aprilov Blvd, 4002, Bulgaria
Multiprofile Hospital for Active Treatment at Ruse
2 Nezavisimost Saint, 7002, Bulgaria
University Multiprofile Hospital for Active Treatment at Pleven
8A Georgi Kotchev Saint, 5800, Bulgaria
The Bailey Clinic at Red Deer
#108 3947 50A Avenue, Alberta, T4N 6V7, Canada
Calgary Metabolic Education & Research Centre at Calgary
#23, 4411-16th Avenue Northwest, Alberta, T3B 0M3, Canada
West Edmonton Diabetes Centre
10230 142 Saint Northwest # 25, Edmonton, Alberta, T5N 3Y6, Canada
Instituto de Endocrinologia IEMYR
Avenida La Coruña Nº 6337 Y San Ignacio, Quito, Ecuador
Bydgoszcz Diabetology and Endocrinology Center at Bydgoszcz
Ul. Baczynskiego 17, 85 - 822, Poland
OSTEOMED Medical Center at Warszawa
Ul. Bialobrzeska 40A, 02 - 341, Poland
Chair and Department of Internal Medicine and Diabetology, Voivodship Brodnowski Hospital at Warszawa
Ul. Kondratowicza 8, 03 - 242, Poland
Diabetology Clinic for Adults, NZOZ Elblag Diabetology Center
Ul. Krolewiecka 146, 82 -300, Poland
TeMeD - Clinical Trials at Rzeszow
Ul. Mazowiecka 56, 35-324, Poland
Provincial Centre of Diabetology and Metabolic Diseases, M.Pirogow Provincial Specialist Hospital at Lodz
Ul. Nowa 30/32, 90-030, Poland
Silesia Osteoporosis Center at Katowice
Ul. Opolska 11/3, 40-084, Poland
TeMeD - Clinical Trials at Nowy Targ
Ul. Wojska Polskiego 14, 34-400, Poland
NZOZ Specialist Centre of Internal Medicine and Diabetology Malgorzata Arciszewska at Bialystok
Ul. Zamenhofa 10/20, 15 - 435, Poland
Celis Aguilera 10B
Fajardo, 00738, Puerto Rico
Puerto Medical Center
San Juan, 364246, Puerto Rico
Clinical Research, Puerto Rico
San Juan, Puerto Rico
"Nicolae Malaxa" Clinical Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Bucharest
12 Vergului Saint Sector 2, 022441, Romania
Timisoara Emergency Clinical County Hospital, Clinic of Diabetes, Nutrition and Metabolic Diseases at Timisoara
156 Iosif Bulbuca Av, 300736, Romania
Satu Mare County Hospital, Department of Diabetology and Nutrition Diseases at Satu Mare
2-3 Eroii Revolutiei Square, 440055, Romania
Private Practice at Galati
25 Constructorilor St, Bl. E5/64, 800371, Romania
Cluj Emergency Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Cluj-Napoca
3-5 Clinicilor Saint, 400006, Romania
Oradea Clinical County Hospital, Department of Diabetes, Nutrition and Metabolic Diseases at Oradea
33 Republicii Saint, 410032, Romania
National Institute of Diabetes, Nutrition and Metabolic Diseases, 1st Clinical Department of Diabetes, Nutrition and Metabolic Diseases at Bucharest
5-7 Ion Movila Saint Sector 2, 020475, Romania
Cardiology Private Practice at Bala Mare
6/72 Independentei Saint, 430123, Romania
Private Practice Nicodiab SRL at Bucharest
92 Polona St, Bl 17 A+B, Sc. 1, Ap. 2, 010507, Romania
Municipal Medical Institution: City Hospital # 2, Municipal Diabetology and Rehabilitation Center
1 3rd -Transportnaya Str., Omsk, 644021, Russia
St. Petersburg State Medical Institution: St. George Municipal Hospital
1 Severny Pr., St.Petersburg, 194354, Russia
Municipal Medical Institution: Medical Unit "Izhmash", Municipal Endocrinology Center
1 Truda Str., Izhevsk, 426067, Russia
St. Petersburg State Medical Institution: Municipal Consulting and Diagnostic Center #1, St. Petersburg Territorial Diabetology Center
10 Siqueirosa Str., Saint Petersburg, 194354, Russia
Federal State Institution: Endocrinology Research Center under the Federal Agency for High-Tech Medical Care, Department of Therapeutic and Surgical Methods for Treatment of Diabetic Foot
11 Dmitriya Ulyanova Str., Moscow, 117036, Russia
Federal State Institution: Endocrinology Research Center under the Federal Agency for High-Tech Medical Care, Department of Training and Psychosocial Rehabilitation of Patients with Diabetes Mellitus
11 Dmitriya Ulyanova Str., Moscow, 117036, Russia
St. Petersburg State Medical Institution: Municipal Hospital of St. Elizabeth
14 Vavilovykh Str., Saint Petersburg, 195257, Russia
State Medical Institution: Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko
190 Rodionova Str., Nizhny Novgorod, 603126, Russia
Medical Institution Municipal Clinical Hospital #67
2 "b" Salyama Adilya Str., Moscow, 123423, Russia
State Medical Institution: Kemerovo Regional Clinical Hospital
22 Oktyabrsky Pr., Kemerovo, 650066, Russia
State Medical Institution: Arkhangelsk Regional Clinical Hospital
292 Lomonosova Pr., Arkhangelsk, 163045, Russia
State Medical Institution: Republican Hospital
3 Pirogova Str., Petrozavodsk, ,, 185019, Russia
St. Petersburg State Medical Institution:Municipal Outpatient Clinic #51
33/35 Kosmonavtov Pr., Saint Petersburg, 196211, Russia
Moscow State Medical Institution Municipal Clinical Hospital #68
4 Shkuleva Str., Moscow, 109263, Russia
St. Petersburg State Medical Institution: City Aleksandrovskaya Hospital
4 Solidarnosti Pr., Saint Petersburg, 193312, Russia
Federal State Medical Institution: All-Russia Center for Urgent Care and Radiation Medicine n.a. A.M. Nikiforov under the Russian Emergency Control Ministry
4/2 Lebedeva Str., St.Petersburg, 194044, Russia
St. Petersburg State Medical Institution: Municipal Multifield Hospital #2
5 Uchebny Per., Saint Petersburg, 194354, Russia
State Higher Educational Institution: Tyumen State Medical Academy under the Federal Agency for Healthcare and Social Development, Multifield Clinic
54 Odesskaya Str., Tyumen, 625023, Russia
"Diabetes" Center Company Limited
56 Sovetskoi Armii Str., Samara, 443067, Russia
State Medical Institution: Consulting and Diagnostic Center of Komi Republic, Diabetology Center
6 Kuratova Str., 167981, Syktyvkar, Russia
State Medical Institution: Murmansk Regional Consulting and Diagnostic Center
6 Pavlova Str., Building 4, Murmansk, 183047, Russia
Municipal Medical Institution: Municipal Clinical Hospital #1, Municipal Diabetology Center
6 Zalesskogo Str., Novosibirsk, 630047, Russia
State Higher Educational Institution: St. Petersburg State Medical University n.a. I.P. Pavlov under the Federal Agency for Healthcare and Social Development
6/8 L. Tolstogo Str., Saint Petersburg, 197022, Russia
State Institution: Moscow Regional Research Clinical Institute n.a. M.F.Vladimirsky
61/2 Shchepkina Str., Moscow, 129110, Russia
State Higher Educational Institution: Ural State Medical Academy under the Federal Agency for Healthcare and Social Development; Family Medicine Clinic
7 Kluchevskaya Str., Ekaterinburg, 620219, Russia
State Medical Healthcare Institution: Chelyabinsk Regional Clinical Hospital
70 Vorovskogo Str., Medgorodok, Chelyabinsk, 454076, Russia
State Medical Institution:Territorial Endocrinology Center, Territorial Diabetology Center
9 Artema Str., Stavropol, 355045, Russia
Regional Endocrinology Center, Diabetology Department at Lviv
1, Ostrozskoho St., Lviv, 79010, Ukraine
Ukrainian Research and Development Center for Endocrine Surgery and Endocrine Organ and Tissue Transplantation under the Ministry of Health of Ukraine, General Endocrine Pathology Department at Kiev
121, Kharkovskoe Shosse, Kiev, 02175, Ukraine
M.V. Sklifosovskyi Regional Clinical Hospital, Endocrinology Department at Poltava
23, Shevchenko Saint, 36024, Ukraine
City Clinical Hospital #9, Endocrinology Department at Dnipropetrovsk
29, Vorontsova Saint, 49023, Ukraine
M.O. Semashko Republican Clinical Hospital, Endocrinology Department at Simferopol
69 Kievskaya Saint, 95017, Ukraine
V.P. Komisarenko Institute for Endocrinology and Metabolism under the Ukrainian Academy of Medical Sciences, Clinical Diabetology Department at Kiev
69, Vyshgorodskaya St., Kiev, 04114, Ukraine
V.P. Komisarenko Institute for Endocrinology and Metabolism under the Ukrainian Academy of Medical Sciences, General Endocrine Pathology Department at Kiev
69, Vyshgorodskaya St., Kiev, 04114, Ukraine
V.Ya. Danylevskyi Institute for Endocrine Pathology under the Ukrainian Academy of Medical Sciences, Clinical Endocrinology Department at Kharkov
Pomerky 27, Kharkov, 61070, Ukraine
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Gerald Bernstein,, MD
Generex Biotechnology Corp.
- STUDY DIRECTOR
Jaime Davidson, MD
Generex Biotechnology Corp.
- PRINCIPAL INVESTIGATOR
Philip Raskin, MD
University of Texas, Southwestern Medical Center at Dallas
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 24, 2008
First Posted
April 29, 2008
Study Start
April 1, 2008
Primary Completion
August 1, 2011
Study Completion
September 1, 2011
Last Updated
June 8, 2011
Record last verified: 2011-06